Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for Relapse After AlloSCT
NCT02981914Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Mar 2017
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Hodgkin lymphoma (HL) and 1 more, sponsored by University of Chicago. Primary endpoint: Number of Patients With Dose-limiting Toxicities at 90 days. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Hodgkin lymphoma (HL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02981914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981914.